FZ01 mAb

Indication: Head and Neck Squamous Cell Carcinoma

Stage: Discovery

FZ01 monoclonal antibody (mAb) targets a secreted metabolic enzyme that confers drug resistance in dividing cancer cells and promotes reactivation of dormant cancer cells. FZ01 is designed to complement standard cancer therapies to extend time in remission.

FZ05 - ADC

Indication: Osteosarcoma and other solid tumors

Stage: Preclinical development

FZ05 is an Antibody-Drug Conjugate. It is comprised of a receptor-specific antibody coupled with a cytotoxic drug payload. The antibody binds to the receptor expressed on the surface of cancer cells. The receptor undergoes internalization and delivers the ADC into cancer cells where the drug payload is released.